ALEMBIC PHARMACEUTICALS Trademark

Trademark Overview

On Friday, October 18, 2019, a trademark application was filed for ALEMBIC PHARMACEUTICALS with the United States Patent and Trademark Office. The USPTO has given the ALEMBIC PHARMACEUTICALS trademark a serial number of 88660605. The federal status of this trademark filing is ABANDONED - AFTER EX PARTE APPEAL as of Monday, November 28, 2022. This trademark is owned by Alembic Pharmaceuticals, Inc.. The ALEMBIC PHARMACEUTICALS trademark is filed in the Pharmaceutical Products category with the following description:

Generic prescription drugs, approved by the U.S. Food and Drug Administration, namely, prescription drugs in the nature of pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations, for the treatment of allergic conjunctivitis, Alzheimer's disease, anxiety, bacterial infections, depression, epilepsy, infection, inflammation and allergies, ulcers, bacterial conjunctivitis, bipolar disorder, bronchoconstriction, erectile dysfunction, fungal infection, glaucoma, herpes, hypercholesterolemia, hypertension, hyperuricemia, hypoparathyroidism, influenza A and B, Parkinson's disease/syndrome, insomnia, intraocular pressure, paralysis, amnesia, unconsciousness, high cholesterol, neuropathic pain, arthritic pain and inflammation, ocular infections, overactive bladder, postoperative inflammation, ocular pain, cough, inflammatory and pruritic manifestations, rheumatoid arthritis, seizure, panic disorder, sleep disorder, transfusional iron overload, and moderate to se...
alembic pharmaceuticals

General Information

Serial Number88660605
Word MarkALEMBIC PHARMACEUTICALS
Filing DateFriday, October 18, 2019
Status603 - ABANDONED - AFTER EX PARTE APPEAL
Status DateMonday, November 28, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesGeneric prescription drugs, approved by the U.S. Food and Drug Administration, namely, prescription drugs in the nature of pills, tablets, capsules, caplets, liquid drops, sachets and pharmaceutical preparations, for the treatment of allergic conjunctivitis, Alzheimer's disease, anxiety, bacterial infections, depression, epilepsy, infection, inflammation and allergies, ulcers, bacterial conjunctivitis, bipolar disorder, bronchoconstriction, erectile dysfunction, fungal infection, glaucoma, herpes, hypercholesterolemia, hypertension, hyperuricemia, hypoparathyroidism, influenza A and B, Parkinson's disease/syndrome, insomnia, intraocular pressure, paralysis, amnesia, unconsciousness, high cholesterol, neuropathic pain, arthritic pain and inflammation, ocular infections, overactive bladder, postoperative inflammation, ocular pain, cough, inflammatory and pruritic manifestations, rheumatoid arthritis, seizure, panic disorder, sleep disorder, transfusional iron overload, and moderate to severe scalp psoriasis; all of the foregoing prescribed by a licensed medical doctor with the prescriptions filled by a retail pharmacy licensed to sell prescription drugs
Disclaimer with Predetermined Text"PHARMACEUTICALS"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 22, 2019
Primary Code005
First Use Anywhere DateTuesday, January 1, 1907
First Use In Commerce DateTuesday, January 1, 1907

Trademark Owner History

Party NameAlembic Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBridgewater, NJ 08807

Trademark Events

Event DateEvent Description
Wednesday, November 30, 2022ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Wednesday, November 30, 2022ABANDONMENT NOTICE MAILED - AFTER EX PARTE APPEAL
Monday, November 28, 2022ABANDONMENT - AFTER EX PARTE APPEAL
Tuesday, November 29, 2022ASSIGNED TO EXAMINER
Monday, November 28, 2022EXPARTE APPEAL TERMINATED
Tuesday, September 13, 2022EX PARTE APPEAL-REFUSAL AFFIRMED
Wednesday, June 29, 2022REPLY BRIEF FILED - CHECK TTAB FILES
Wednesday, May 25, 2022NOTIFICATION OF EXAMINERS STATEMENT E-MAILED
Wednesday, May 25, 2022EXAMINERS STATEMENT E-MAILED
Wednesday, May 25, 2022EXAMINERS STATEMENT - COMPLETED
Monday, March 28, 2022JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, December 8, 2021NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Wednesday, December 8, 2021ACTION DENYING REQ FOR RECON E-MAILED
Wednesday, December 8, 2021SUBSEQUENT FINAL REFUSAL WRITTEN
Tuesday, November 2, 2021JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, October 27, 2021EXAMINERS REQUEST FOR REMAND TO TTAB
Wednesday, September 8, 2021JURISDICTION RESTORED TO EXAMINING ATTORNEY
Thursday, June 17, 2021NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED
Thursday, June 17, 2021ACTION DENYING REQ FOR RECON E-MAILED
Thursday, June 17, 2021ACTION CONTINUING FINAL - COMPLETED
Thursday, June 17, 2021EXAMINER'S AMENDMENT ENTERED
Thursday, June 17, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, June 17, 2021EXAMINERS AMENDMENT E-MAILED
Thursday, June 17, 2021EXAMINERS AMENDMENT -WRITTEN
Monday, May 17, 2021JURISDICTION RESTORED TO EXAMINING ATTORNEY
Friday, March 26, 2021JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, March 24, 2021TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, January 6, 2021NOTIFICATION OF SUBSEQUENT FINAL EMAILED
Wednesday, January 6, 2021SUBSEQUENT FINAL EMAILED
Wednesday, January 6, 2021SUBSEQUENT FINAL REFUSAL WRITTEN
Tuesday, December 1, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 1, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 1, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 30, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 30, 2020NON-FINAL ACTION E-MAILED
Thursday, July 30, 2020NON-FINAL ACTION WRITTEN
Tuesday, July 14, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, July 14, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Sunday, July 12, 2020ASSIGNED TO LIE
Wednesday, July 1, 2020TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, July 1, 2020EX PARTE APPEAL-INSTITUTED
Wednesday, July 1, 2020JURISDICTION RESTORED TO EXAMINING ATTORNEY
Wednesday, July 1, 2020EXPARTE APPEAL RECEIVED AT TTAB
Tuesday, April 21, 2020NOTIFICATION OF FINAL REFUSAL EMAILED
Tuesday, April 21, 2020FINAL REFUSAL E-MAILED
Tuesday, April 21, 2020FINAL REFUSAL WRITTEN
Saturday, March 28, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, March 27, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, March 27, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 27, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, January 27, 2020NON-FINAL ACTION E-MAILED
Monday, January 27, 2020NON-FINAL ACTION WRITTEN
Friday, January 24, 2020ASSIGNED TO EXAMINER
Tuesday, October 22, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Related Keywords

pharmaceuticals alembic pain inflammation disorder disease bacterial infection ocular infections conjunctivitis prescription